131I-MIBG--a new agent in diagnosis and treatment of pheochromocytoma.
Cardiology
; 72 Suppl 1: 137-42, 1985.
Article
en En
| MEDLINE
| ID: mdl-4053121
ABSTRACT
The newly developed radiopharmaceutical, 131I-metaiodobenzylguanidine (131I-MIBG), has been shown to be efficacious for the location of intra- and extra-adrenal, primary pheochromocytomas and metastatic, malignant pheochromocytomas (11.4% false-negative and 1.8% false-positive in patients with proven pheochromocytomas). Preliminary experience in selected patients with malignant pheochromocytoma suggest that therapy using large doses of 131I-MIBG results in partial tumor regression and improvement in catecholamine hypersecretion in some cases.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Feocromocitoma
/
Neoplasias de las Glándulas Suprarrenales
Tipo de estudio:
Diagnostic_studies
Idioma:
En
Revista:
Cardiology
Año:
1985
Tipo del documento:
Article